Phenobarbital will decrease the extent or impact of ivosidenib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Coadministration of ivosidenib with robust CYP3A4 inducers decreased ivosidenib plasma concentrations. Hydrocodone, phenobarbital. Profound sedation, respiratory despair, coma, and demise may end result if coadministered. Phenobarbital will lower the level or impact of glecaprevir/pibrentasvir by rising metabolism.
Tamsulosinphenobarbital will lower the level or effect of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Sotorasibphenobarbital will lower the extent or impact of sotorasib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Sorafenibphenobarbital will lower the level or impact of sorafenib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Sirolimusphenobarbital will lower the extent or effect of sirolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Simvastatinphenobarbital will decrease the extent or effect of simvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Silodosinphenobarbital will lower the extent or impact of silodosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
Ketoconazolephenobarbital will lower the extent or impact of ketoconazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Itraconazolephenobarbital will lower the level or effect of itraconazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Isradipinephenobarbital will lower the extent or impact of isradipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Imatinibphenobarbital will decrease the extent or effect of imatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Ibuprofen IVphenobarbital will lower the level or effect of ibuprofen IV by affecting hepatic enzyme CYP2C9/10 metabolism.
Acetylcholine stimulates the muscles of the intestines that propels digesting meals by way of the gut. It additionally impacts the secretion of fluids by salivary glands and the stomach. Phenobarbital produces sedation.
Phenobarbital will lower the extent or impact of enfortumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Phenobarbital will decrease the level or impact of encorafenib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Phenobarbital decreases ranges of elvitegravir/cobicistat/emtricitabine/tenofovir DF by affecting hepatic/intestinal enzyme CYP3A4 metabolism. May lead noxema for sunburns to loss of virologic response and attainable resistance. Phenobarbital will decrease the extent or effect of eltrombopag by affecting hepatic enzyme CYP1A2 metabolism.
Phenobarbital will lower the extent or effect of lumateperone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Phenobarbital will lower the extent or impact of lovastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Phenobarbital will lower the extent or impact of losartan by affecting hepatic enzyme CYP2C9/10 metabolism. Phenobarbital will decrease the level or impact of loratadine by P-glycoprotein efflux transporter.
When treating ITP, coadministration of avatrombopag with a average or strong dual CYP2C9/3A4 inducer requires an increased avatrombopag beginning dose. Refer to drug monograph for specific suggestions. Avatrombopagphenobarbital will decrease the level or effect of avatrombopag by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Phenobarbital will lower the level or impact of tucatinib by Other . Coadministration of tucatinib with a robust or moderate CYP2C8 inducer decreases tucatinib plasma concentrations.